<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218240</url>
  </required_header>
  <id_info>
    <org_study_id>1UG3DA049694-01</org_study_id>
    <nct_id>NCT04218240</nct_id>
  </id_info>
  <brief_title>Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal</brief_title>
  <acronym>PGB-LOF</acronym>
  <official_title>Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM): Can it Increase the Success of Transition to Naltrexone?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II double-blind placebo-controlled parallel group clinical trial that will randomize&#xD;
      90 subjects to investigate whether pregabalin (PGB) combined with Lofexidine (LFX) can reduce&#xD;
      opioid withdrawal-related subjective effects, and investigate, whether the PGB/LFX&#xD;
      combination can increase the proportion of patients with an opioid use disorder (OUD) who&#xD;
      complete detoxification and transition to antagonist treatment with extended-release&#xD;
      injectable naltrexone (XR-NTX).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An inpatient detoxification study where pregabalin (PBG) will be given orally at a starting&#xD;
      dose of up to 600 mg daily (group 1) tapered to 100 mg daily over 7 days; given with&#xD;
      lofexidine (LFX) starting at 2.16 mg daily and declining to 0.72 mg over 7 days. On day 8,&#xD;
      subjects are offered an injection of XR-NTX if they provide a urine sample that is negative&#xD;
      for opioids and buprenorphine and pass a naloxone challenge. All subjects, regardless of&#xD;
      whether or not they receive XR-NTX, will be given a referral and appointment for follow-up&#xD;
      treatment when they leave the inpatient detoxification program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>for the primary comparison of longitudinal subjective withdrawal measures, comparing the groups on rate of decrease across detox days, using a linear group by time effect for the mixed effects models described above. We have one primary outcome, so use an alpha level of 0.05, and we use two-sided tests. 90 subjects, 30 from each of three sites, who will be randomized into two groups, with 30 assigned to Lofexidine plus Placebo, and 60 to Lofexidine plus a starting daily dose of 400 mg of pregabalin and increasing to 600mg Pregabalin on day 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The Penn Investigational Drug Service (IDS) will prepare blinded pregabalin capsules by over encapsulation of the drug into capsules shells matching the placebo capsules. Blinded pregabalin capsules will be packaged into blister packs along with lofexidine tablets, in separate compartments that are labeled for dosing times on days 1-7 and ship them to the research sites.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>withdrawal</measure>
    <time_frame>7 days</time_frame>
    <description>reduction of withdrawal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete detoxification</measure>
    <time_frame>7 days</time_frame>
    <description>Proportion of subjects who complete the 7 day detoxification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Opioid Withdrawal</condition>
  <arm_group>
    <arm_group_label>PGB/LFX;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.54 mg lofexidine and 200 mg Pregabalin on days 1 -7 with taper for pregabalin and lofexidine starting on day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lofexidine and PLACEBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.54 mg lofexidine and Placebo (PLB) on days 1-7 with taper for lofexidine starting on day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 200 MG capsules</intervention_name>
    <description>oral pregabalin 200 mg capsules given with a taper on day 5</description>
    <arm_group_label>PGB/LFX;</arm_group_label>
    <other_name>lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>oral Placebo</description>
    <arm_group_label>Lofexidine and PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine 0.18Mg Tab</intervention_name>
    <description>lofexidine 0.18 tab given with a taper starting on day 5</description>
    <arm_group_label>Lofexidine and PLACEBO</arm_group_label>
    <arm_group_label>PGB/LFX;</arm_group_label>
    <other_name>lucemyra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women 18+ years of age&#xD;
&#xD;
          -  Meet Diagnostic and Statistical Manual- Fifth Edition (DSM-5) criteria for an Opioid&#xD;
             Use Disorder with physiologic features&#xD;
&#xD;
          -  Interested in opioid antagonist treatment&#xD;
&#xD;
          -  Have used opioids in 20 of the past 30 days&#xD;
&#xD;
          -  Have a stable address in the local area; not planning to move; have documents for&#xD;
             identification check&#xD;
&#xD;
          -  Absence of medical or psychiatric conditions that are likely to interfere with study&#xD;
             participation&#xD;
&#xD;
          -  Have a 12 lead ECG demonstrating a QTc ≤450 msec and a QRS interval ≤120 msec at&#xD;
             screening. The site PI has the final determination for inclusion into the study for&#xD;
             ECGs unless there is a question of QT prolongation or other factors. If consultation&#xD;
             is needed, the University of Pennsylvania cardiologists and the medical monitor should&#xD;
             be consulted.&#xD;
&#xD;
          -  For females, a negative pregnancy test, uses adequate contraception if of childbearing&#xD;
             potential, does not engage in heterosexual behavior&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current psychotic disorder (bipolar I, schizophrenia, major depression with psychotic&#xD;
             features,) as defined by the Mini-International Neuropsychiatric Interview (MINI).&#xD;
&#xD;
          -  Has an alcohol, benzodiazepine, or other sedative disorder with physiological features&#xD;
             that requires medication for detoxification&#xD;
&#xD;
          -  Has a history of allergy or other serious adverse event due to treatment with&#xD;
             pregabalin, XR-NTX, or lofexidine&#xD;
&#xD;
          -  Pending incarceration in the next 30 days&#xD;
&#xD;
          -  Homicidal or otherwise behaviorally disturbed to the extent that immediate attention&#xD;
             is required.&#xD;
&#xD;
          -  High Risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on the&#xD;
             Columbia Suicide Severity Rating Scale (C-SSRS) at screening&#xD;
&#xD;
          -  Blood pressure ≤90 mm Hg (systolic) or ≤60 mm Hg (diastolic). If this value is out of&#xD;
             normal range, the investigator and a study clinician will decide if the subject can be&#xD;
             included on a case-by-case basis.&#xD;
&#xD;
          -  Heart rate and/or pulse &lt;56bpm at screening-sitting&#xD;
&#xD;
          -  Creatinine Clearance &lt;60 mL/min&#xD;
&#xD;
          -  Current seizure disorder (excluding childhood febrile seizures)&#xD;
&#xD;
          -  Inability to read and/or understand English. For example, does not understand the&#xD;
             informed consent as demonstrated by failing to correctly answer 9/10 questions on the&#xD;
             quiz&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Currently taking antihypertensive medication, sympathomimetic drugs, or a&#xD;
             thiazolidinedione antidiabetic (diuretics allowed)&#xD;
&#xD;
          -  An ALT and/or AST that is at &gt;3 times the top limit of normal&#xD;
&#xD;
          -  History of cirrhosis or impaired renal function&#xD;
&#xD;
          -  Currently receiving opioids for pain management&#xD;
&#xD;
          -  Participated in a treatment study where medication was administered in the last 30&#xD;
             days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Watson</last_name>
    <role>Study Director</role>
    <affiliation>Office of Research Administration, Univ. of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>kyle kampman, M.D.</last_name>
    <phone>215-746-2764</phone>
    <email>kampman@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George E Woody, M.D.</last_name>
    <phone>325-746-7702</phone>
    <email>woodyg@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mountain Manor Treatment Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fishman, MD</last_name>
      <phone>410-916-6839</phone>
      <email>mjfishman@comcast.net</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Wenzel, PhD</last_name>
      <phone>561-542-4282</phone>
      <email>kwenzel@mountainmanor.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>John Mariani</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Kampman, M.D.</last_name>
      <phone>215-746-2764</phone>
      <email>kampman@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>George Woody, M.D.</last_name>
      <phone>215-746-7702</phone>
      <email>woodyg@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Professor Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lofexidine</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not at this time</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

